Document Detail

Valproate-Induced Hyperammonemic Encephalopathy: A Brief Review.
MedLine Citation:
PMID:  22587482     Owner:  NLM     Status:  Publisher    
ABSTRACT Background: This brief review presents a comprehensive evaluation of valproate induced encepalopathy (VHE) and also discusses potential mechanisms of the condition. Scope: Sodium Valproate (VPA) is an effective antiepileptic drug used in neurology as well as in psychiatry, in adults and children. VHE requires early diagnosis and management. Focused research efforts in understanding the condition will help decrease its incidence. Delay in recognition of VHE can result in the development of potentially life-threatening complications. Findings: Management options are described. Since VPA frequently causes a modest rise in plasma ammonia levels which is asymptomatic, it is important to recognize the symptoms of VHE promptly and to correlate them with the plasma ammonia levels. Conclusions: Although there are several case reports on VHE, this review is a comprehensive evaluation of its causes and potential mechanisms. Rapid diagnosis and management will help in reducing VHE-related morbidity.
Chandani Lewis; Abhishek Deshpande; George E Tesar; Roman Dale
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-5-15
Journal Detail:
Title:  Current medical research and opinion     Volume:  -     ISSN:  1473-4877     ISO Abbreviation:  -     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-5-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  An assessment of the efficacy and safety of diclofenac potassium liquid-filled capsules in patients ...
Next Document:  Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naïve Japanese patients with ty...